Chemocentryx Stock Story


USD 50.52  0.09  0.18%   

The stock goes through a very aggressive trading activities. As some millenniums are still trying to avoid healthcare space, I will try to concentrate on Chemocentryx a little further in order to understand its potential as a viable investment. We will examine the reasons why it is still possible for the company to generate above-average margins given the current economic outlook.
Published over a month ago
View all stories for Chemocentryx | View All Stories

Chemocentryx Sentiment by News Outlets

benzinga news
zacks News
Investors Business Daily at Macroaxis
Investing News at Macroaxis
Barrons News
fool News
prnewswire News
Macroaxis News:

Chemocentryx Historical Investor Sentiment

Investor biases related to Chemocentryx's public news can be used to forecast risks associated with investment in Chemocentryx. The trend in average sentiment can be used to explain how an investor holding Chemocentryx can time the market purely based on public headlines and social activities around Chemocentryx. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Chemocentryx's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Chemocentryx's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Chemocentryx's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Chemocentryx.

Chemocentryx Twitter Pulse

Investors have realized that leveraging social media to get the fastest information affecting stock prices isn't a theory anymore, it is a reality, and Twitter offers a platform that can outpace even the most trustworthy news aggregators. The influence of social media outlets on stock markets and stock prices of entities such as Chemocentryx has been proven in recent years. We extract public sentiment from Twitter posts that could be utilized to determine whether Chemocentryx's prices will increase or decrease.
Twitter's metrics such as likes, followers, and engagement can be good indicators of the reliance and probability of reaction to a specific tweet regarding Chemocentryx. Our Twitter sentiment analysis of Chemocentryx Stock helps investors make informed decisions by leveraging the power of the community. It is a perfect supplementary tool for any beginner or an experienced trader.

Chemocentryx Maximum Pain Price across 2022-08-19 Option Contracts

Chemocentryx's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Chemocentryx close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Chemocentryx's options.

Should you drop your Chemocentryx (NASDAQ:CCXI) positions following the current analyst consensus?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Chemocentryx has an asset utilization ratio of 41.23 percent. This implies that the company is making $0.41 for each dollar of assets. An increasing asset utilization means that Chemocentryx is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Chemocentryx? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

What is happening with Chemocentryx this year

Annual and quarterly reports issued by Chemocentryx are formal financial statements that are published yearly and quarterly and sent to Chemocentryx stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Chemocentryx often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How does Chemocentryx utilize its cash?

To perform a cash flow analysis of Chemocentryx, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Chemocentryx is receiving and how much cash it distributes out in a given period. The Chemocentryx cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Chemocentryx Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (75.62 Million)

Acquisition by Herron Jennifer Lyn of 17237 shares of Chemocentryx subject to Rule 16b-3

Legal trades by Chemocentryx insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Chemocentryx insider trading alert for grant of common stock by Herron Jennifer Lyn, the corporate stakeholder, on 30th of June 2022. This event was filed by Chemocentryx Inc with SEC on 2022-06-30. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.


Earning per share calculations of Chemocentryx is based on official Zacks consensus of 4 analysts regarding Chemocentryx's future annual earnings. Given the historical accuracy of 76.36%, the future earnings per share of the company is estimated to be -1.66 with the lowest and highest values of -1.91 and -1.25, respectively. Please note that this consensus of annual earnings estimates for the firm is an estimate of EPS before non-recurring items and including employee stock options expenses.

Is Chemocentryx a risky opportunity?

Let's check the volatility. Chemocentryx is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Chemocentryx (NASDAQ:CCXI) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. locking in a share of a Chemocentryx stock makes you a part-owner of that company.

Chemocentryx Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Chemocentryx. The Chemocentryx consensus assessment is calculated by taking the average estimates from all of the analysts covering Chemocentryx

Strong Buy
Strong Buy583.33
Strong Sell00.0

Chemocentryx is getting out of control

Current downside deviation is at 4.34. Chemocentryx exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Chemocentryx individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Chemocentryx future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Chemocentryx's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Chemocentryx's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Chemocentryx Implied Volatility

Chemocentryx's implied volatility exposes the market's sentiment of Chemocentryx stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Chemocentryx's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Chemocentryx stock will not fluctuate a lot when Chemocentryx's options are near their expiration.

Our Final Perspective on Chemocentryx

While few other entities under the biotechnology industry are still a bit expensive, Chemocentryx may offer a potential longer-term growth to stockholders. The bottom line, as of the 13th of June 2022, we believe that at this point, Chemocentryx is not too volatile with low probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our primary 90 days buy-hold-sell recommendation on the company is Strong Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Chemocentryx. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to